Walid Hleihel

CEO

CEO of Astremiha Therapeutics, Walid Hleihel leads the strategic development, defines the Business plan and ensures its evolution based on data, and defines the target drug profile to develop.

Mireille Laforge

PhD, HDR, CR CNRS, CSO

Founder

I discovered broad-spectrum antiviral drugs with immune modulation and research immunometabolism's role in infectious diseases and neurodevelopmental disorders to develop new diagnostic and treatment strategies.

Pierre Gressens

MD, PhD, DRE INSERM, Co-CSO

Co-Founder

Director of research and clinical initiatives focusing on neurodevelopmental disorders and treatments related to premature birth, with over 400 published articles, contributing significantly to medical science.

Raphael de Saint Exupéry

Innovation Management

Co-Founder

MSc in Management, specializing in Data Analysis, Innovation Management, and Pharma Consulting, offering expertise in strategic decision-making and innovative solutions within the pharmaceutical and healthcare industries.

Léna d'Agata

COO

PhD in cell biology and physiopathology. Brings scientific rigor and project coordination to the operational core of Astremiha.

François Rossier

CFO

François Rossier brings diverse professional expertise from defense and interministerial roles to his current positions in private sector as Key Account Director for France and Switzerland, alongside volunteering as Secretary General of Ailes de France Foundation and ambassador for Institut Robert Debré Brain Child Project.

Brice Lançon

Independent Administrator

Over 30 years of experience in European defense and aerospace cooperation. Strategic advisor in corporate governance and business development.

Thierry Roussel

Independent Administrator

Entrepreneur and executive, co-founded Direct Energie and Senioradom, sold multiple companies, now invests in energy, support for vulnerable people, food, and agriculture. His leadership has been instrumental in driving growth and innovation, and he continues to influence the energy and healthcare sectors through strategic investments and advisory roles.

Philippe Rouanet De Berchoux

Medical Advisor

General practitioner and former Armed Forces Health Service director, specializes in strategic health leadership and crisis management.

Bruno Villoutreix

Drug Development Advisor

Research director at INSERM, specializes in AI-driven drug development and therapeutic protein design, with notable contributions to cancer treatment and drug repurposing.

Michael Spedding

Drug Development Advisor

President of Spedding Research Solutions SAS, focuses on ALS and long COVID drug development, with a prolific pharmacology career, over 230 publications, and 20+ patents.

Nicolas Chomont

Scientific Advisor, Immunopathology/Infectiology

Associate Professor at the University of Montreal, researches HIV latency and eradication, focusing on the persistence of HIV-infected cells and T lymphocyte proliferation.

Vincent Calvez

Scientific Advisor, Infectiology/Viral Infection

Professor of Clinical Virology at Sorbonne University, leads the Virology Department at Pitié-Salpêtrière Hospital, directs the ANRS Virology Network, and has significant contributions in antiviral and oncology therapeutics.